Posted 6/27/2023 4:31 PM (GMT 0)
I don't know much about this new drug except that it's part of the TNF family. Companies are reporting promising Phase 2 results and plan to move quickly into Phase 3. Supposedly better efficacy and better safety than some current options.
Roivant/Pfizer: https://investor.roivant.com/news-releases/news-release-details/roivant-reports-chronic-period-data-rvt-3101-tuscany-2-phase-2b
Prometheus (bought by Merck): https://academic.oup.com/ecco-jcc/article/17/Supplement_1/i162/7009290
Teva: https://www.biopharmadive.com/news/teva-tl1a-drug-crohn-ulcerative-colitis-turnaround/650680/
- development is behind the other two, but they are hoping to be best in class.